Total Payments
$358,370
2024 Payments
$95,671
Companies
24
Transactions
247
Medicare Patients
1,378
Medicare Billing
$248,107
Payment Breakdown by Category
Consulting$237,358 (66.2%)
Other$70,500 (19.7%)
Travel$29,984 (8.4%)
Research$13,100 (3.7%)
Food & Beverage$7,429 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $237,358 | 63 | 66.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,760 | 11 | 10.0% |
| Travel and Lodging | $29,984 | 70 | 8.4% |
| Honoraria | $25,796 | 9 | 7.2% |
| Unspecified | $13,100 | 7 | 3.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $8,945 | 3 | 2.5% |
| Food and Beverage | $7,429 | 84 | 2.1% |
Payments by Type
General
$345,270
240 transactions
Research
$13,100
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $103,621 | 83 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $39,811 | 28 | $0 (2019) |
| GlaxoSmithKline, LLC. | $38,100 | 23 | $0 (2024) |
| CTI BioPharma Corp. | $29,424 | 12 | $0 (2023) |
| ABBVIE INC. | $24,398 | 27 | $0 (2024) |
| Sumitomo Pharma Co., Ltd. | $22,067 | 14 | $0 (2023) |
| Celgene Corporation | $21,127 | 13 | $0 (2022) |
| SOBI, INC | $18,696 | 5 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $12,518 | 5 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $6,483 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $95,671 | 47 | Incyte Corporation ($44,757) |
| 2023 | $96,024 | 59 | GlaxoSmithKline, LLC. ($24,401) |
| 2022 | $66,972 | 62 | Incyte Corporation ($29,136) |
| 2021 | $12,796 | 9 | Incyte Corporation ($5,266) |
| 2020 | $21,273 | 9 | Celgene Corporation ($10,598) |
| 2019 | $20,716 | 32 | JAZZ PHARMACEUTICALS INC. ($16,096) |
| 2018 | $41,392 | 24 | Jazz Pharmaceuticals Inc. ($23,715) |
| 2017 | $3,526 | 5 | Incyte Corporation ($3,405) |
All Payment Transactions
247 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $103.36 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $162.09 | General |
| Category: Oncology | ||||||
| 11/12/2024 | SOBI, INC | VONJO (Drug) | Consulting Fee | Cash or cash equivalent | $3,700.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/04/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Consulting Fee | Cash or cash equivalent | $3,040.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $5,800.00 | Research |
| Study: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | ||||||
| 10/25/2024 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $130.48 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/23/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $42.77 | General |
| Category: Hematology/Oncology | ||||||
| 09/27/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $347.00 | General |
| 09/27/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $62.25 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.99 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.99 | General |
| 09/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/26/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $301.39 | General |
| 09/11/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $401.95 | General |
| Category: Hematology/Oncology | ||||||
| 09/09/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Oncology / Rare Diseases | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $4,452.50 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $366.96 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $245.70 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $185.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $185.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $119.10 | General |
| Category: Hematology/Oncology | ||||||
| 09/05/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $2.34 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $5,800 | 1 |
| A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $2,175 | 1 |
| A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $1,100 | 2 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsedx2FRefractory Myelofibrosis | ABBVIE INC. | $1,100 | 1 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/00BFRefractory Myelofibrosis (TRANSFORM-2) | ABBVIE INC. | $725.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 366 | 612 | $346,890 | $55,267 |
| 2022 | 5 | 364 | 719 | $392,220 | $64,683 |
| 2021 | 6 | 349 | 934 | $490,700 | $85,945 |
| 2020 | 6 | 299 | 637 | $284,460 | $42,211 |
Total Patients
1,378
Total Services
2,902
Medicare Billing
$248,107
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 96 | 160 | $116,800 | $19,854 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 164 | $89,380 | $13,506 | 15.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 200 | $75,000 | $10,683 | 14.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 38 | 38 | $39,710 | $5,885 | 14.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 50 | $26,000 | $5,341 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 115 | 228 | $124,260 | $19,329 | 15.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 145 | $76,125 | $13,445 | 17.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 126 | 211 | $79,125 | $12,508 | 15.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 57 | 93 | $68,820 | $12,359 | 18.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 42 | 42 | $43,890 | $7,042 | 16.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 430 | $217,150 | $41,022 | 18.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 119 | 251 | $136,795 | $21,998 | 16.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 39 | 66 | $47,520 | $8,698 | 18.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 88 | 142 | $53,250 | $8,102 | 15.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $30,305 | $5,053 | 16.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 16 | $5,680 | $1,072 | 18.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 185 | $96,200 | $13,468 | 14.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 119 | $58,905 | $11,523 | 19.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 107 | 211 | $74,905 | $9,676 | 12.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 32 | $22,080 | $3,325 | 15.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 36 | 39 | $13,845 | $1,688 | 12.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 12 | 12 | $9,685 | $1,336 | 13.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 12 | 13 | $6,760 | $880.66 | 13.0% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 18 | 26 | $2,080 | $315.76 | 15.2% |
About Dr. Raajit Rampal, MD
Dr. Raajit Rampal, MD is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1407019722.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raajit Rampal, MD has received a total of $358,370 in payments from pharmaceutical and medical device companies, with $95,671 received in 2024. These payments were reported across 247 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($237,358).
As a Medicare-enrolled provider, Rampal has provided services to 1,378 Medicare beneficiaries, totaling 2,902 services with total Medicare billing of $248,107. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location New York, NY
- Active Since 07/07/2008
- Last Updated 01/08/2013
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1407019722
Products in Payments
- JAKAFI (Drug) $55,368
- VYXEOS (Drug) $39,811
- Vonjo (Drug) $29,424
- VONJO (Drug) $18,696
- XPOVIO (Drug) $12,518
- TIBSOVO (Drug) $12,461
- INREBIC (Drug) $8,651
- ELZONRIS (Drug) $5,261
- BESREMI (Drug) $4,765
- REBLOZYL (Biological) $3,750
- AYVAKIT (Drug) $2,172
- Leukine (Drug) $2,105
- VENCLEXTA (Drug) $1,901
- RYDAPT (Drug) $1,880
- PEMAZYRE (Drug) $1,845
- Fabhalta (Drug) $103.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in New York
Craig Thompson, Md, MD
Medical Oncology — Payments: $2.1M
Medical Oncology $2.1M
Andrew Seidman, Md, MD
Medical Oncology — Payments: $1.7M
Medical Oncology $1.7M
Dr. Joshua Richter, M.d, M.D
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Ghassan Abou-Alfa, Md, MD
Medical Oncology — Payments: $1.2M
Medical Oncology $1.2M
Edward Gelmann
Medical Oncology — Payments: $944,679
Medical Oncology $944,679
Miguel Perales, Md, MD
Medical Oncology — Payments: $759,555
Medical Oncology $759,555